83 results
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:00am
, net
Tax receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment
Investment at fair value through profit and loss …
Income taxes payable
Leases
Deferred acquisition payments
Leases
Deferred acquisition payments
Deferred income tax liability
Total liabilities
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Current report (foreign)
5:29pm
Indebtedness.
(hh) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material … Adverse Change, each of the Company and its Subsidiaries (i) has made or filed all U.S. and Canadian federal, state, provincial and local income tax
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
as described herein may have tax consequences both in Canada and the United States. Such consequences for investors who are resident in, or citizens … of, Canada or the United States may not be described fully herein. See "Certain U.S. Federal Income Tax Considerations". The enforcement by investors
6-K/A
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
15 Feb 24
Current report (foreign) (amended)
3:12pm
receivable, net
Sales tax receivable
Income taxes receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment … acquisition payments
Deferred income tax liability
Total liabilities
SHAREHOLDERS' EQUITY
Share capital
Contributed surplus
Accumulated other
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Dec 23
Current report (foreign)
8:38am
tax receivable
Income taxes receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment
Investment at fair … income tax liability
Total liabilities
SHAREHOLDERS' EQUITY
Share capital
Contributed surplus
Accumulated other comprehensive loss
Accumulated
424B5
s0pg3xatpd
7 Dec 23
Prospectus supplement for primary offering
4:53pm
6-K
EX-10.1
1fy8k4jk7r pc1ghm0
6 Dec 23
Current report (foreign)
5:19pm
6-K
EX-8.1
s1ed8smtbdsu3 8vr533
6 Dec 23
Current report (foreign)
5:19pm
6-K
o7krm2g8j5 7cmapt78
6 Dec 23
Current report (foreign)
5:19pm
424B5
xwql2hnrzjwbqnmq
5 Dec 23
Prospectus supplement for primary offering
4:02pm
6-K
EX-99.2
kzhz4xx
14 Sep 23
Current report (foreign)
8:02am
6-K
EX-10.1
f4y v9l6m
15 Aug 23
Current report (foreign)
5:50pm
424B5
76rgn6pn
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
EX-23.3
2h1240nziz898b18m2
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
gjvtn05je3 3ao
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-4.3
jh8yv8sbhpstt skd
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-4.4
35e5l
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
EX-99.1
wd1m1
10 Jul 23
Annual report (Canada)
4:32pm
40-F
302qydbfky 7qcsl
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.2
ycwist
10 Jul 23
Annual report (Canada)
4:32pm